Investors
Diagnostics companies are building the infrastructure precision medicine runs on. The product to launch, the channel to lead with, the indication to anchor a development pipeline, the category to enter next, the growth strategy when the core market matures — these are the decisions that determine where a Dx company wins, how it reaches its market, and which categories are worth building for.

Select Capabilities
Biomarker and Diagnostics Strategy
This is where precision medicine starts – whether you’re trying to find the right tools to uncover new biomarkers, identify CDx partners, launch an IVD, or understand how your assay will fit into the clinical journey, DeciBio has you covered. Nobody knows biomarkers and CDx better than DeciBio.
Selected Work

PE-Backed Life Sciences Tools Platform Development
Voice-of-Customer Research
Customer Segmentation
Pricing Strategy
Due Diligence
Competitive Analysis

Investment Diligence into Leading Oncology Diagnostic Provider
Voice-of-Customer Research
Competitive Analysis
Revenue Projection
Due Diligence








.png)
.png)




